Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Capricor Therapeutics

< Previous 1 2 Next >
Capricor Therapeutics Reports Second Quarter 2015 Business & Financial Highlights
Company to Host Conference Call and Webcast at 4:30 p.m. EDT, Today, August 13, 2015 
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics to Hold Second Quarter 2015 Business Update and Financial Results Conference Call on August 13, 2015 at 4:30 p.m. EDT
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics Appoints Deborah Ascheim, M.D. as Chief Medical Officer
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics Appoints Houman Hemmati M.D., Ph.D. to Vice President of Medical and Clinical Development for New Therapies
Company to Drive Forward Development of Promising Therapies Including Exosome Platform 
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics and CureDuchenne to Host Webinar on June 19, 2015 at 3:00 p.m. ET
Presentation to Discuss Capricor's HOPE-DUCHENNE Trial 
Tickers CAPR
From GlobeNewswire News Releases
Capricor Announces Receipt of FDA Clearance for the Phase I/II Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Related Cardiomyopathy
HOPE-DUCHENNE Trial Evaluating the Safety and Preliminary Efficacy of Treatment Expected to Begin in 3Q15 
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics to Participate in Two Upcoming Investor Conferences in June
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics Reports First Quarter 2015 Financial & Business Highlights
Company to Host Conference Call and Webcast at 4:30 p.m. EDT, Today, May 12, 2015 
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics to Hold First Quarter 2015 Business Update and Financial Results Conference Call on May 12, 2015 at 4:30 p.m. EDT
Tickers CAPR
From GlobeNewswire News Releases
Capricor Granted FDA Orphan Drug Designation for Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy
Tickers CAPR
From GlobeNewswire News Releases
Capricor Completes Enrollment of Initial Phase of DYNAMIC Clinical Trial of Cardiosphere-Derived Cell Therapy for Treatment of Advanced Heart Failure
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics Completes Enrollment of Phase II Clinical Trial for Cenderitide to Treat Heart Failure
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25, 2015 in New York
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics Reports Fourth Quarter and Full Year 2014 Financial & Business Highlights
Conference Call Scheduled for Wednesday, March 18, 2015 (4:30 p.m. EDT) 
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics to Hold Fourth Quarter 2014 Business Update Conference Call on March 18, 2015 at 4:30 p.m. EDT
Tickers CAPR CAPR
From GlobeNewswire News Releases
Capricor Therapeutics to Present at the 27th Annual ROTH Conference
Tickers CAPR CAPR
From GlobeNewswire News Releases
Capricor Announces Enrollment of Its Phase II Clinical Trial for Cenderitide to Treat Heart Failure
Natriuretic Peptide to be Administered Subcutaneously in Ambulatory Heart Failure Patients 
Tickers CAPR PODD
From GlobeNewswire News Releases
Capricor Therapeutics Announces Uplisting to NASDAQ Capital Market
NASDAQ Trading of "CAPR" to Commence on March 9, 2015 
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics Appoints Thomas Copmann, Ph.D. as Vice President of Regulatory Affairs and Drug Development
- New Position Added as Company's Pipeline Progresses in Clinical Development - 
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics Announces $7 Million Private Placement of Common Stock
Institutional Investors Include: Broadfin Capital, LLC and Sabby Capital, LLC 
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics and CureDuchenne to Host Webinar on January 21, 2015 at 3:00 p.m. ET
Presentation to Discuss Capricor's Duchenne Muscular Dystrophy Clinical Program 
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics Initiates the DYNAMIC Clinical Trial for the Treatment of Advanced Heart Failure
Trial Funded Through $3M Grant From National Institutes of Health 
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics Announces $10 Million Private Placement of Common Stock
Investors Include: Cedars-Sinai Medical Center, CureDuchenne Ventures LLC, Select Board Members and Capricor Management 
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present a Company Overview and Serve as an Expert Panelist at Piper Jaffray's 26th Annual Healthcare Conference
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics Announces Favorable ALLSTAR Phase I Safety Results
Preliminary Efficacy Data Shows Encouraging Results 
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics Announces Positive Pre-Clinical Data for Cardiosphere-Derived Cells (CDCs) on Duchenne Muscular Dystrophy Cardiomyopathy
Capricor Intends to File for Approval to Conduct Clinical Trial of CAP-1002 in Duchenne Cardiomyopathy 
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics Reports Third Quarter 2014 Financial & Business Highlights
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics to Hold Duchenne Muscular Dystrophy Data Presentation Call on November 18, 2014 at 9:30 a.m. ET
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics to Hold Third Quarter 2014 Business Update Conference Call on November 12, 2014 at 4:30 p.m. ET
Tickers CAPR
From GlobeNewswire News Releases
Capricor Therapeutics Announces Acquisition of Intellectual Property Rights to Family of Natriuretic Peptides From Medtronic, Inc.
Tickers CAPR MDT
From GlobeNewswire News Releases
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.